G01N 2333/4718
Lipocortins
G01N2333/4718 (Lipocortins) appears on 50 US grants and 64 published applications in this corpus.
Search patents in G01N- Granted patents
- 50
- Published applications
- 64
- Assignees
- 61
- Inventors
- 155
- Latest grant
- 11 Jul 2023
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1996 | 1 | 0 |
| 1997 | 2 | 0 |
| 1998 | 3 | 0 |
| 1999 | 4 | 0 |
| 2000 | 2 | 0 |
| 2001 | 5 | 2 |
| 2002 | 1 | 1 |
| 2003 | 7 | 5 |
| 2004 | 1 | 2 |
| 2005 | 1 | 2 |
| 2006 | 1 | 4 |
| 2007 | 1 | 1 |
| 2008 | 1 | 4 |
| 2009 | 2 | 3 |
| 2010 | 2 | 11 |
| 2011 | 2 | 4 |
| 2012 | 2 | 4 |
| 2013 | 3 | 2 |
| 2014 | 2 | 2 |
| 2015 | 0 | 4 |
| 2016 | 2 | 3 |
| 2017 | 1 | 3 |
| 2018 | 2 | 2 |
| 2019 | 0 | 2 |
| 2020 | 1 | 2 |
| 2021 | 0 | 0 |
| 2022 | 0 | 0 |
| 2023 | 1 | 1 |
By publication year. Applications have been published since 2001.
Recent patents
- Anti-annexin A2 monoclonal antibodies11 Jul 2023US 11,697,681 B2Agency for Science, Technology and Research
- Anti-annexin A2 monoclonal antibodies19 May 2020US 10,654,921 B2Agency for Science, Technology and Research
- Diagnosis of benign and cancerous growths by measuring circulating tumor stem cells and serum AnnexinA24 Sep 2018US 10,067,134 B2Board of Regents, The University of Texas System
- Use of annexin A3 as a diagnostic and prognostic biomarker and therapeutic target for treating hepatocellular carcinoma19 Jun 2018US 10,000,558 B2Versitech Limited
- Diagnosis of benign and cancerous growths by measuring circulating tumor stem cells and serum AnnexinA228 Feb 2017US 9,581,599 B2Board of Regents, The University of Texas System
- Vesicle and use thereof16 Feb 2023US 2023/0051925 A1Ev Cell Biotech (Guangzhou) Co., Ltd.
- Anti-annexin a2 monoclonal antibodies24 Dec 2020US 2020/0399353 A1Agency for Science, Technology and Research
- Plasma biomarker for ovarian cancer1 Oct 2020US 2020/0309780 A1Adelaide Research & Innovation Pty Ltd
- Anti-annexin a2 monoclonal antibodies13 Jun 2019US 2019/0177405 A1Agency for Science, Technology and Research
- Free Functional Annexin Levels in Plasma as a Biomarker of Cardiovascular Risk28 Mar 2019US 2019/0094244 A1Inserm (Institut National De La Sante Et De La Recherche Medicale)
Most cited
By later US patents
- Focusing of microparticles in microfluidic systems442US 6,592,821 B1Caliper Technologies Corp. · 2003
- Focusing of microparticles in microfluidic systems377US 6,506,609 B1Caliper Technologies Corp. · 2003
- Use of an anticoagulant as a diagnostic agent30US 5,627,036 ABoehringer Ingelheim International GmbH · 1997
- Rapid methods for identifying modifiers of cellular apoptosis activity19US 6,270,980 B1Idun Pharmaceuticals, Inc. · 2001
- Methods for cancer prognosis and diagnosis19US 6,511,806 B1Oncotech, Inc. · 2003